Background: Unlike the tremendous progress made in atrial fibrillation ablation, the greatest unmet clinical need is for innovative ablation treatments for scar-related ventricular tachycardia (VT) – ...

Results at Six Months VCAS is a prospective, multicenter feasibility trial evaluating the safety and performance of the ...

Findings presented at the International VT Symposium and published simultaneously in Circulation. CARDIFF-BY-THE-SEA, Calif.

An Abbott (NYSE: ABT) official posted on social media to announce FDA breakthrough device designation for a new ablation ...

Atrial fibrillation (AF) has traditionally been classified by episode duration, whereas rhythm control outcomes—via antiarrhythmic drugs or catheter ablation (CA)—have typically been evaluated using a ...

Background Atrial fibrillation (AF) is linked to significant morbidity and mortality, with ischaemic stroke being a leading ...

Atrial fibrillation can cause confusion. Most people with AFib, a type of irregular heartbeat, know nothing about it until ...

The company has now treated 500,000 patients with its pulsed field ablation system, in a competitive category poised for ...

S AN FRANCISCO -- Noninvasive stereotactic radiotherapy (RT) for refractory ventricular tachycardia (VT) achieved outcomes ...

Jonathon Frye was sitting in his driveway when all of a sudden, his heart started to race. “It felt like I was running a ...

Atrial fibrillation (AF) is a predominant arrhythmia, posing challenges due to its association with increased morbidity, mortality, and healthcare resource ...

The atrial fibrillation market thrives on rising disease prevalence, technological advancements in AI and remote monitoring, and the need for innovative treatments. Companies harnessing these ...